Renal Substudies of EPO-TBI and POLAR
The EPO-TBI and POLAR trials presented a unique opportunity to investigate the effect of potentially renoprotective therapies (EPO and hypothermia) on kidney function in TBI patients, and the ability of several novel biomarkers, including NGAL and cystatin C to detect kidney injury and response to treatment.
Endorsement: The Renal Substudies of EPO-TBI and POLAR were endorsed by the ANZICS Clinical Trials Group (CTG).
Collaboration: The Renal Substudies of EPO-TBI and POLAR were conducted in collaboration with the ANZICS Clinical Trials Group (ANZICS-CTG) EPO-TBI and POLAR Investigators.
Moore EM, Bellomo R, Nichol A, Harley N, MacIsaac C, Cooper DJ. The incidence of acute kidney injury in patients with traumatic brain injury. Renal Failure 2010;32(9):1060–5. PMID: 20863210.
Moore EM, Tobin A, Reid D, Bellomo R. Reply: AKI Classification: One Size Doesn't Fit All. J Cardiothorac Vasc Anesth. 2016;30:e36-7. PMID: 27236489.
Skrifvars M, Moore E, Mårtensson J, Bailey M, French C, Presneill J, Nichol A, Little L, Duranteau J, Huet O, Haddad S, Arabi Y, McArthur C, Cooper DJ, Bellomo R. Erythropoietin in traumatic brain injury associated acute kidney injury – A randomised controlled trial. Acta Anaesthesiologica Scandinavica 2019:63:200-7. PMID: 30132785.
Contact: For further information about this project, please contact Elizabeth Moore by email.